Search Results

Flagship Pioneering’s ProFound Therapeutics will use its proprietary technology to mine the expanded proteome for novel cardiovascular therapeutics. Novartis has promised to pay up to $750 million per target, though it has not specified how many targets it will go after.

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in development to date” in the competitive Lp(a) space, where drugs are designed to lower the risk of cardiovascular events such as heart attack and stroke.

Nationally recognized cardiothoracic surgeon, Douglas R. Johnston, MD, has been named surgical director of Northwestern Medicine’s Bluhm Cardiovascular Institute and chief of the division of cardiac surgery at Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine.

Inspira Technologies OXY B.H.N Ltd., a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent with Northwestern Memorial Hospital in Chicago, Illinois.

Atherosclerotic Cardiovascular Disease Market Outlook 2025-2035:

Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) IDE clinical trial, commenced with two procedures performed at the Cardiovascular Institute of South Paris (ICPS) (https://icps.fr).